PTPRO

Across TCGA pan-cancer cohorts, PTPRO mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PTPRO’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PTPRO mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PTPRO is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where PTPRO tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPRO mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−1.123	<.001	10	view →
LUAD	Male	All	−0.603	<.001	8	view →
LSCC	All	II,III,IV	−0.571	<.001	7	view →
HNSC	All	All	+0.283	.039	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PTPRO–CCRCC

Open the CCRCC breakdown →